BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967]
URL: https://www.wjgnet.com/1948-5182/full/v22/i40/8967.htm
Number Citing Articles
1
Yaling Hui, Ting Tang, Jing Wang, Huanhuan Zhao, Hong-Ying Yang, Junmin Xi, Baoxin Zhang, Jianguo Fang, Kun Gao, Yueting Wu. Fusaricide is a Novel Iron Chelator that Induces Apoptosis through Activating Caspase-3Journal of Natural Products 2021; 84(8): 2094 doi: 10.1021/acs.jnatprod.0c01322
2
Joshua P. Gray, Natalia Suhali-Amacher, Sidhartha D. Ray. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2017; 39: 197 doi: 10.1016/bs.seda.2017.07.001
3
Man Theerasilp, Punlop Chalermpanapun, Kanyawan Ponlamuangdee, Dusita Sukvanitvichai, Norased Nasongkla. Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapyRSC Advances 2017; 7(18): 11158 doi: 10.1039/C6RA26669J
4
Yukimasa Makita, Shumpei Murata, Yoshiki Katou, Kuniko Kikuchi, Hiroshi Uejima, Mika Teratani, Yasutaka Hoashi, Eriya Kenjo, Satoru Matsumoto, Masahiro Nogami, Kentaro Otake, Yuji Kawamata. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinomaBiochemical and Biophysical Research Communications 2017; 493(1): 800 doi: 10.1016/j.bbrc.2017.08.088
5
Sai Krishna Athuluri‐Divakar, Yujin Hoshida. Generic chemoprevention of hepatocellular carcinomaAnnals of the New York Academy of Sciences 2019; 1440(1): 23 doi: 10.1111/nyas.13971
6
Azmi Khan, Pratika Singh, Amrita Srivastava. Iron: Key player in cancer and cell cycle?Journal of Trace Elements in Medicine and Biology 2020; 62: 126582 doi: 10.1016/j.jtemb.2020.126582
7
Mindy M. Hugo, Ipsita A. Banerjee. Development of new amphiphilic bio-organic assemblies for potential applications in iron-binding and targeting tumor cellsSoft Materials 2019; 17(1): 57 doi: 10.1080/1539445X.2018.1548357
8
Hongliang You, Dao Wang, Linlin Wei, Jiao Chen, Huanhuan Li, Yufeng Liu, Yongzhong Hou. Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK PathwaysJournal of Oncology 2022; 2022: 1 doi: 10.1155/2022/8281267
9
Christopher J. Greene, Kristopher Attwood, Nitika J. Sharma, Kenneth W. Gross, Gary J. Smith, Bo Xu, Eric C. Kauffman. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patientsOncotarget 2017; 8(63): 107052 doi: 10.18632/oncotarget.22323
10
Valentina Pita-Grisanti, Kaylin Chasser, Trevor Sobol, Zobeida Cruz-Monserrate. Understanding the Potential and Risk of Bacterial Siderophores in CancerFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.867271
11
Ola Ibrahim, Jeff O’Sullivan. Iron chelators in cancer therapyBioMetals 2020; 33(4-5): 201 doi: 10.1007/s10534-020-00243-3
12
Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasiroxBMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07167-8
13
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida. Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular CarcinomaApplied Sciences 2021; 11(4): 1882 doi: 10.3390/app11041882
14
Nan Zhou, Yan Cui, Rui Zhu, Yuhuan Kuang, Wenhui Ma, Jianyuan Hou, Yumeng Zhu, Shubo Chen, Xin Xu, Ke Tan, Pengxiu Cao, Xianglin Duan, Yumei Fan. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivoGynecologic Oncology 2022; 166(1): 126 doi: 10.1016/j.ygyno.2022.05.006
15
Hui Wang, Danfeng Lin, Qianqian Yu, Zhouqi Li, Cameron Lenahan, Ying Dong, Qichun Wei, Anwen Shao. A Promising Future of Ferroptosis in Tumor TherapyFrontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.629150
16
Wojciech Szlasa, Martyna Gachowska, Karolina Kiszka, Katarzyna Rakoczy, Aleksander Kiełbik, Kamila Wala, Julia Puchała, Katarzyna Chorążykiewicz, Jolanta Saczko, Julita Kulbacka. Iron chelates in the anticancer therapyChemical Papers 2022; 76(3): 1285 doi: 10.1007/s11696-021-02001-2
17
Johanna M. Buschhaus, Shrila Rajendran, Brock A. Humphries, Alyssa C. Cutter, Ayşe J. Muñiz, Nicholas G. Ciavattone, Alexander M. Buschhaus, Tatiana Cañeque, Zeribe C. Nwosu, Debashis Sahoo, Avinash S. Bevoor, Yatrik M. Shah, Costas A. Lyssiotis, Pradipta Ghosh, Max S. Wicha, Raphaël Rodriguez, Gary D. Luker. Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancerOncogene 2022;  doi: 10.1038/s41388-022-02385-9
18
Jiaqi Qin, Ce Zhou, Mengqi Zhu, Shurui Shi, Lianyun Zhang, Yanhong Zhao, Changyi Li, Yinsong Wang, Yue Wang. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinomaPhotodiagnosis and Photodynamic Therapy 2020; 31: 101907 doi: 10.1016/j.pdpdt.2020.101907
19
Shuhei Shinoda, Seiji Kaino, Shogo Amano, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivoOncotarget 2018; 9(47): 28434 doi: 10.18632/oncotarget.25421
20
Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cellsCancer & Metabolism 2022; 10(1) doi: 10.1186/s40170-022-00284-x
21
Axel Steinbrueck, Adam C. Sedgwick, Hai-Hao Han, Michael Y. Zhao, Sajal Sen, Dan-Ying Huang, Yi Zang, Jia Li, Xiao-Peng He, Jonathan L. Sessler. In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeuticsChemical Communications 2021; 57(46): 5678 doi: 10.1039/D0CC08156F
22
Christopher J. Greene, Nitika J. Sharma, Peter N. Fiorica, Emily Forrester, Gary J. Smith, Kenneth W. Gross, Eric C. Kauffman. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivationFree Radical Biology and Medicine 2019; 133: 295 doi: 10.1016/j.freeradbiomed.2018.12.013
23
Myriam Y. Hsu, Erica Mina, Antonella Roetto, Paolo E. Porporato. Iron: An Essential Element of Cancer MetabolismCells 2020; 9(12): 2591 doi: 10.3390/cells9122591
24
Jonathan H. Joachim, Kosha J. Mehta. Hepcidin in hepatocellular carcinomaBritish Journal of Cancer 2022;  doi: 10.1038/s41416-022-01753-2
25
Toshiaki Ohara, Yasuko Tomono, Xing Boyi, Sun Yingfu, Kazuhiro Omori, Akihiro Matsukawa. A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell linesOncotarget 2018; 9(67): 32751 doi: 10.18632/oncotarget.25973
26
Rikki A. M. Brown, Kirsty L. Richardson, Tasnuva D. Kabir, Debbie Trinder, Ruth Ganss, Peter J. Leedman. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and ImmunologyFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00476
27
Maura Argenziano, Alessandra Di Paola, Chiara Tortora, Daniela Di Pinto, Elvira Pota, Martina Di Martino, Silverio Perrotta, Francesca Rossi, Francesca Punzo. Effects of Iron Chelation in OsteosarcomaCurrent Cancer Drug Targets 2021; 21(5): 443 doi: 10.2174/1568009620666201230090531
28
Arezoo Sodagar Taleghani, Pedram Ebrahimnejad, Amir Heydarinasab, Azim Akbarzadeh. Adsorption and controlled release of iron-chelating drug from the amino-terminated PAMAM/ordered mesoporous silica hybrid materialsJournal of Drug Delivery Science and Technology 2020; 56: 101579 doi: 10.1016/j.jddst.2020.101579
29
Bo Li, Zhipeng Liao, Yingxi Mo, Weilin Zhao, Xiaohui Zhou, Xiling Xiao, Wanmeng Cui, Guofei Feng, Suhua Zhong, Yushan Liang, Chunping Du, Guangwu Huang, Ping Li, Xue Xiao, Xiaoying Zhou, Rensheng Wang, Zhe Zhang. Inactivation of 3-hydroxybutyrate dehydrogenase type 2 promotes proliferation and metastasis of nasopharyngeal carcinoma by iron retentionBritish Journal of Cancer 2020; 122(1): 102 doi: 10.1038/s41416-019-0638-8
30
Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicineJournal of Hepatology 2018; 68(3): 526 doi: 10.1016/j.jhep.2017.09.016